| TOTAL | $21.6M |
| VENTURE FUNDING TOTAL | $21.6M |
| Venture Round, 11/08 New Enterprise Associates MPM Capital OrbiMed Advisors | $21.6M |
| DEBT TOTAL | $6.3M |
| Debt, 8/10 Lighthouse Capital Partners | $6.3M |
ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.
